These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 14697414)

  • 21. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer.
    Khattak MA; Martin HL; Beeke C; Price T; Carruthers S; Kim S; Padbury R; Karapetis CS
    Clin Colorectal Cancer; 2012 Dec; 11(4):247-54. PubMed ID: 22763194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
    Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
    Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of radiotherapy for prostate cancer.
    Swanson GP; Riggs MW; Earle JD
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):406-11. PubMed ID: 15145156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    Pascale M; Azinwi CN; Marongiu B; Pesce G; Stoffel F; Roggero E
    BMC Cancer; 2017 Sep; 17(1):651. PubMed ID: 28923109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distant metastasis in triple-negative breast cancer.
    Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
    Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis.
    Chen J
    PLoS One; 2018; 13(8):e0200909. PubMed ID: 30102707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Gandaglia G; Fossati N; Stabile A; Bandini M; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2017 Aug; 72(2):289-292. PubMed ID: 27574820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical features and prognostic factors of brain metastasis from colorectal cancer].
    Sun Z; Sun Y; Tan L; He J; Li X; She C; Li W
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):63-8. PubMed ID: 26796809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: Results from the multicentre FRANCOGYN study group.
    Ouldamer L; Bendifallah S; Body G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Bricou A; Lavoué V; Lévêque J; Daraï E; Ballester M;
    Eur J Surg Oncol; 2019 Apr; 45(4):672-678. PubMed ID: 30722948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study.
    Wu JX; Lin LM; He JY; Hong L; Li JL
    Medicine (Baltimore); 2016 Feb; 95(6):e2789. PubMed ID: 26871838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.